4,112 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by Syon Capital LLC

Syon Capital LLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 4,112 shares of the biotechnology company's stock, valued at approximately $500,000.

A number of other hedge funds have also bought and sold shares of the company. Manchester Capital Management LLC lifted its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $36,000. Steward Partners Investment Advisory LLC raised its holdings in Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in Sarepta Therapeutics by 95.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock worth $54,000 after buying an additional 216 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded down $0.01 during midday trading on Wednesday, hitting $60.84. The company had a trading volume of 328,732 shares, compared to its average volume of 1,423,579. The company has a market cap of $5.90 billion, a price-to-earnings ratio of 48.67 and a beta of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $48.01 and a 12-month high of $173.25. The company has a fifty day moving average of $75.46 and a two-hundred day moving average of $104.84. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 7.70% of the company's stock.

Analyst Ratings Changes

SRPT has been the subject of a number of analyst reports. Morgan Stanley cut their target price on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research note on Friday, April 11th. HC Wainwright restated a "neutral" rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, April 16th. Needham & Company LLC decreased their target price on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research report on Thursday, April 3rd. Scotiabank reduced their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday, March 20th. Finally, Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price target for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $158.70.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.